Profile of SENTI BIOSCIENCES INC(NASDAQ:SNTI) stock

SENTI BIOSCIENCES INC2.25

NASDAQ:SNTI (12/2/2022, 7:02:58 PM)-0.05 (-2.17%)

After market: 2.25 0 (0%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Biotechnology

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	11-10 2022-11-10/bmo	Earnings (Next)	N/A N/A
Ins Owners	9.62%	Inst Owners	N/A
Market Cap	146.27M	Shares	65.01M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	82.22
IPO	05-26 2021-05-26

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Senti Biosciences, Inc. operates as a biotechnology company. The company is headquartered in South San Francisco, California. The company went IPO on 2021-05-26. The firm is developing cell and gene therapies engineered with its gene circuit platform technologies to cure diseases. Its advanced gene-circuit product candidates are directed at allogeneic CAR-NK cells for oncology. Its preclinical stage product candidates include SENTI-202, SENTI-301 and SENTI-401. The company is developing its SENTI-202 product candidate as a Logic Gated (OR + NOT) allogeneic CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML), cells while sparing the healthy bone marrow. Its SENTI-301 product candidate is a multi-Armed allogeneic CAR-NK cell therapy that it is developing for the treatment of hepatocellular carcinoma (HCC). Its SENTI-401 product candidate is a Logic-Gated allogeneic CAR-NK cell therapy that it is developing to target and eliminate colorectal cancer (CRC) cells. Gene circuit platform is its technology platform.

Company Info

SENTI BIOSCIENCES INC

2 Corporate Drive, First Floor

South San Francisco CALIFORNIA

P: 16503823281.0

Employees: 0

SNTI News

10 days ago - Senti Biosciences, Inc.Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting

– Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment...

10 days ago - Senti Biosciences, Inc.Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting

23 days ago - Senti Biosciences, Inc.Senti Bio Reports Third Quarter Financial Results and Pipeline Updates

- SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33and/or FLT3 expressing hematologic malignancies...

23 days ago - Senti Biosciences, Inc.Senti Bio Reports Third Quarter Financial Results and Pipeline Updates

a month ago - Senti Biosciences, Inc.Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting

Poster presentation to highlight preclinical data for SENTI-202 which employs Logic Gating gene circuit technology in off-the-shelf CAR-NK cells designed...